Based on its previously demonstrated activity and tolerability in ES-SCLC, I-DXd will be examined in the phase 3 IDeate-Lung02 trial.
Evolving Approaches in SCLC: Practical Strategies and Future Directions
Advertisement
Advertisement
Trending on OncLive
1
ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma
2
ASCO Guideline Update Broadens First-Line Treatment Options for HER2+ Gastroesophageal Cancer
3
Dr Wainberg on INCB161734 Activity in Refractory Pancreatic Cancer
4
European Commission Approves Teclistamab Plus Daratumumab for R/R Myeloma
5